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TB  is now  the  single  pathogen  that  causes  the  greatest  mortality  in the  world,  at over  1.6 million  deaths
each year.  The  widely  used  the  90  year  old  BCG  vaccine  appears  to have  minimal  impact  on  the  world-
wide  incidence  despite  some  efﬁcacy  in infants.  Novel  vaccine  development  has  accelerated  in the past
15 years,  with  15  candidates  entering  human  trials;  two vaccines  are  now  in large-scale  efﬁcacy  stud-
ies. Modeling  by three  groups  has consistently  shown  that  mass  vaccination  that includes  activity  in
the  latently  infected  population,  especially  adolescents  and  young  adults,  will likely  have  the  largest
impact  on  new  disease  transmission.  At present  the ﬁeld  requires  better  validated  animal  models,  better
understanding  of  a correlate  of  immunity,  new  cost-effective  approaches  to Proof  of  Concept  trials,  and
increased  appreciation  by the  public  health  and scientiﬁc  community  for  the  size of the problem  and  the
need  for  a vaccine.  Such  a vaccine  is likely  to  also  play  a  role  in  the era  of increasing  antibiotic  resistance.
Ongoing  efforts  and  studies  are  working  to implement  these  needs  over the next  5 years,  which  will  lead
to  an  understanding  that  will increase  the  likelihood  of  a successful  TB vaccine.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd. This  is  an  open  access  article  under  the  CC. The disease and pathogen
In March 1993, the World Health Organization (WHO) des-
gnated tuberculosis (TB), a disease caused by Mycobacterium
uberculosis (Mtb), a global public health emergency. Since 1993
here are more than 1.5 million deaths from TB each year, making
t the number nine overall cause of mortality worldwide. Nearly
 billion people have died of TB over the past few centuries, an
stounding number, and TB is a leading cause of mortality in HIV-
nfected individuals and in women of childbearing age. Ninety-nine
er cent of the TB deaths and 95% of the over 9.5 million new
ases each year occur in the low and middle-income countries that
omprise 85% of the world’s population. One-third of the world’s
opulation is estimated to be latently infected and 5–10% of these
eople may  go on to develop active TB disease; however, the risk
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se  of the WHO  logo is not permitted. This notice should be preserved along with
he article’s original URL.
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is considerably higher in the presence of predisposing factors. As
such, in part the epidemic of TB in sub-Saharan Africa has been
fueled by HIV disease, and the increasing incidence of diabetes in
Asia further threatens attempts at control.
One of the highest priorities of TB research is to develop vaccines
that are more efﬁcacious for preventing TB than Mycobacterium
bovis bacillus Calmette–Guérin (BCG), the only vaccine available
to (partially) protect against TB disease [1]. Research and devel-
opment is one of the three pillars of the WHO  TB strategy, and
will play a crucial role in accelerating the reductions in TB inci-
dence and mortality required to reach global TB targets to reduce
TB deaths by 95% and to reduce new infections by 90% between
2015 and 2035. Better control of TB than that provided by BCG
could be achieved by vaccines that protect individuals from initial
infection with M. tuberculosis (Mtb), prevent those infected from
progressing to active disease, or decrease the capacity for trans-
mission by those with active disease. Different vaccines may  be
required to induce immune responses in diverse populations, such
as infants, young adults, those already latently infected with Mtb,
and those co-infected with Mtb  and HIV. Experts in TB prevention
and control mostly agree that the largest vaccine impact would
result from mass vaccination of all adolescents/young adults in high
burden countries, regardless of their infection status, even with a
vaccine that is only 50–60% efﬁcacious over a 10 year duration. Such
an initial vaccine strategy could prevent up to 50 million cases of
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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ncident TB cases in high-burden settings during the ﬁrst 35 years
fter its introduction [2]. This impact would likely save millions
f lives and billions of dollars in treatment and control costs. It
s also important to note that strains of Mtb  that are resistant to
tandard anti-tuberculous drugs, including multiply drug resistant
MDR) and extensively drug-resistant (XDR) strains are becoming
ore common. While Mtb  is likely to continue to evolve resistance
gainst drugs develop to combat it, it is highly unlikely that such
esistance would result in a concomitant development of resistance
gainst otherwise effective TB vaccines.
. Overview of current efforts
.1. Vaccines currently available and their limitations
The human immune system can contain tuberculosis infection
n the majority of cases following infection, and a partially effec-
ive vaccine for infants exists. These data, as well as evidence that
rior Mtb  infection may  protect against later disease [3], paint an
ptimistic picture for the development of a vaccine. On the other
and, because Mtb  has co-evolved with humans over many years
nd may  use the human immune system to maintain its propaga-
ion [4], and because prior active pulmonary tuberculosis does not
rotect and may  actually be a risk factor for reinfection and disease,
ome scientiﬁc skepticism has arisen concerning the prospect for
eveloping an effective vaccine.
BCG is a live, attenuated vaccine that is widely administered
o infants in most areas endemic for TB. BCG has been shown to
e effective for the prevention of more serious extrapulmonary
uberculosis in young children, such as tuberculous meningitis and
iliary tuberculosis [5]. A meta-analysis of prospective trials and
ase-control studies concluded efﬁcacy against pulmonary TB in
nfants and adolescents to be approximately 50%, with a range from
 low of zero to a high of eighty per cent [6]. When delivered to
ewborns, however, BCG is not fully effective in preventing adult
ulmonary TB, which constitutes the bulk of the global morbidity
nd mortality disease burden.
.2. General approaches to vaccine development for this disease
or low and middle income country markets
Most successful, licensed vaccines available today induce neu-
ralizing antibodies that provide protective immunity. Animal and
uman studies of TB, however, suggest that a robust cellular
mmune response is required for protection against Mtb infection
nd disease [7,8]. For this reason, the majority of current clinical
B vaccine candidates are based on a variety of vectors, adjuvants
nd antigens that induce classical TH1 cytokines such as IFN- or
NF- from either CD4+ or CD8+ T cells.
These clinical candidates are based on a variety of vaccine
pproaches, such as inactivated whole cell or whole cell extracts
Mycobacterium indicus pranii,  Mycobacterium vaccae,  DAR-901
Mycobacterium obuense), RUTI and Mycobacterium smegmatis),
iral-vectored candidates (vaccinia based MVA85A, inﬂuenza, and
uman adenovirus 5 and 35 and chimpanzee adenovirus), fusion
rotein subunits with TH1-inducing adjuvants (M72/AS01, Hybrid
/CAF01, Hybrid 1/IC31, H4/IC31, H56/IC31 and ID93/GLA-SE), and
ive recombinant BCG or attenuated TB vaccines (VPM 1002, Aeras
22, rBCG30, and MTBVAC). DNA vaccines are being developed in
ifferent countries, notably emerging economies, but have not yet
ntered into human clinical trials. To date, clinical trials charac-
erizing these candidate vaccines have included studies of safety
nd immunogenicity in diverse populations, including healthy, TB-
aïve adults and infants, latently infected adolescents and adults,4 (2016) 2911–2914
HIV-infected adults, as well as patients undergoing drug treatment
for TB.
An initial Phase IIB proof-of-concept (PoC) efﬁcacy trial in 2797
BCG-vaccinated infants boosted at 4–6 months of age with a viral-
vectored vaccine containing one antigen (MVA85A) showed no
efﬁcacy against TB disease or infection [9]. Whether this disap-
pointing outcome was  due to the magnitude of the immunologic
response, the single dose of Ag85A antigen studied, the population
vaccinated, or an incorrect immunologic hypothesis is not clear. A
large, Phase IIB trial in 3600 HIV-uninfected, adults latently infected
with Mtb  is under way in three African countries (South Africa,
Kenya, Zambia) using the GSK M72  adjuvanted fusion protein
vaccine. This study should further our understanding of poten-
tial correlates of protection, as well as the role of TH-1 induced
immunological responses in preventing the development of disease
in latently infected individuals. Data are expected in 2018.
In addition to these large-scale PoC trials, a new set of human
studies are under way, based on the use of innovative trials designs
intended to show the biologic activity of vaccine candidates using
more focused populations speciﬁcally selected to reduce sample
size. The ﬁrst of these new trial designs is testing whether a novel
vaccine (H4/IC31) or the use of BCG re-vaccination can prevent
sustained infection by Mtb  (as opposed to disease). The trial uses
novel blood tests in which BCG vaccination does not interfere with
the test result – a common obstacle with the longtime, standard
diagnostic, the tuberculin skin test. The study is enrolling adoles-
cents in South Africa with a high rate of incident Mtb  infection,
thereby requiring only 330 subjects per arm rather than the two
thousand or more needed in the classic PoC trials. The second inno-
vative trial design is to study the ability of a vaccine to prevent
the 4–6% relapse and/or reinfection rate typically observed follow-
ing successful treatment of active TB. A “Prevention of Recurrence”
trial using the ID93 candidate will likely begin shortly and require
approximately 450 subjects per arm. All of these trials represent
an attempt to make decisions earlier in development (a “shift to
the left”), including the initial attempts to coordinate a more glob-
ally focused preclinical consortium effort, given the 20–50 million
dollar cost needed to conduct classical efﬁcacy disease endpoint
studies. Of note, a 10,000-person Phase 3 study is also underway
in Guanxi province, China, to test the efﬁcacy of a killed M.  vaccae
lysate vaccine to prevent TB in adults with latent disease.
3. Technical and regulatory assessment
At present there are no accepted correlates of protection that,
unto themselves, could support a decision to license a TB vaccine.
It is presumed that prevention of actual disease will continue to be
the primary endpoint of Phase 2b or 3 trials. However, whether reg-
ulators will accept stringent deﬁnitions based on clinical outcomes
and supporting evidence for a licensure decision without a direct
culture of Mtb  is not yet clear. Whether regulators would accept
data from the nucleic acid-detecting GeneXpert, or infection-based
endpoints (such as IGRA tests) rather than endpoints based on overt
clinical or culture-positive disease remain open issues. Similarly,
discussions concerning the use of population or community ran-
domized study designs rather than large double-blind individual
randomized studies are ongoing. There is clearly a need to engage
the TB community, along with the regulatory experts, to begin dis-
cussions concerning these and other licensure issues [10].
We  have no clear preclinical models upon which to identify the
“best” vaccine Mtb  antigens, as many TB vaccine animal challenge
models have a narrow dynamic range of responses that do not allow
for easy differentiation among candidates. This limitation is being
addressed by reﬁnement of the mouse, guinea pig and macaque
models to better approximate natural infection by Mtb  and better
T.G. Evans et al. / Vaccine 34 (2016) 2911–2914 2913
Table  1
Development status of current vaccine candidates.
Candidate name/identiﬁer Developer Type Phase I Phase IIa Phase IIb Phase III
Ad5 Ag85A [McMaster University, CanSino] Human adenovirus 5 1 antigen X
TB/Flu-04L [RIBSP] Attenuated inﬂuenza X
DAR-901 [Dartmouth, Aeras] Heat-killed NTM X
ChAdOx1.85A/MVA85A [Oxford] Chimp adenovirus/modiﬁed vaccinia X
MTBVAC [TBVI, Zaragoza, Biofabri] Live attenuated TB X
ID93  + GLA-SE [IDRI, Aeras] 4 Ag adjuvanted fusion protein X
VPM 1002 [Max Planck, VPM, TBVI, Serum Institute of India] Modiﬁed recombinant BCG X
H1  + IC31 [Statens Serum Institut (SSI), TBVI, EDCTP] 2 Ag adjuvanted fusion protein X
RUTI [Archivel Farma, S.L] Lysate of Mtb X
H4/Aeras-404 + IC31 [SSI, Sanoﬁ-Pasteur, Aeras, Intercell] 2 Ag adjuvanted fusion protein X
H56/Aeras-456 + IC31 [SSI, Aeras, Intercell] 3 Ag adjuvanted fusion protein X
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M.  Vaccae [Anhui ZhifeiLongcon, China] Ly
imic  human disease. The use of low dose challenge, sophisticated
ET/CT imaging techniques, and novel vaccine candidates (such
s H56, Cytomegalovirus (CMV) approaches, and aerosolized ade-
ovirus vaccines) have recently shown that the macaque model
ay  potentially be useful to delineate correlates of vaccine-induced
rotection.
In human biomarker studies, gene expression patterns of
nﬂammatory biosignatures have correlated with risk for TB disease
rogression, and with the extent of radiographic involvement in
oth active and latent TB cases [11,12]. In response to these data, TB
accine developers are pursuing a systems immunology approach
n which gene expression signatures are compared in samples from
arious time points [13]. These signatures are then correlated to
ither speciﬁc measures of immunogenicity, or to protection in efﬁ-
acy studies. This method allows for a broader unbiased net to be
ast in assessing immune responses, and in searching for a correlate
f vaccine-induce protection.
. Status of vaccine R&D activities
Sixteen candidate vaccines have moved forward into clinical
tudies in the last 10 years. Over a dozen candidates currently
re under active clinical study, summarized in Table 1 [14]. These
tudies are supported by a combination of multinational pharma-
eutical companies (GSK, Crucell, Sanoﬁ-Pasteur, Serum Institute of
ndia), smaller vaccine developers (Staten Serum Institut, Infectious
isease Research Institute, Vakzine Projekt Management, BioFabri,
nd others), academics (MPIIIB, US and European Universities),
nd TB vaccine-focused non-proﬁts (Aeras and TBVI). Support has
rimarily been through the Bill &Melinda Gates Foundation, gov-
rnmental organizations such as the EC, DGIS, DIFD, NORAD and the
IH, and through direct investments of companies. The business
ase for TB vaccines, as recently developed by a working group of
eras, TBVI, EC, EIB, and BMGF, is compelling, with potential returns
n investment that range into the billions of dollars. Due to the high
erceived scientiﬁc risks, however, it has been difﬁcult to engage
ndustry, whether large or small, from entering into this ﬁeld with-
ut substantial early subsidization from granting organizations.
Early signals of potential efﬁcacy may  be obtained from the four
arge trials mentioned above over the next 3 years: prevention of
isease by vaccination with the GSK or M.  vaccae product; preven-
ion of infection through use of the Sanoﬁ candidate; and possibly
revention of recurrence using the IDRI candidate. If any of these
rove promising, there will be considerable momentum to carry
ne or more of these into larger efﬁcacy studies. The use of a live,
ttenuated TB vaccine, and the exploration of whole cell vaccines,
ill continue with a focus on better deﬁning an immune response
urrogate.
Other innovative leads that will be aggressively pursued over
he next 5 years will include the use of aerosolized adenoviraljuvanted fusion protein X
f NTM X
and other candidates, either alone or in combination. The com-
bination of aerosolized adenoviral vectored vaccines followed by
modiﬁed vaccinia Ankara has been especially promising in both
preclinical models and in early human trials. CMV  candidates will
likely move forward in both the TB and HIV area, as they induce
prolonged and high levels of effector T cells in the mucosal loca-
tion where the pathogen ﬁrst encounters the human host. Other
promising leads include intranasal attenuated parainﬂuenza or
inﬂuenza-vectored viruses for induction of mucosal immunity, self-
replicating RNA candidates, and electroporated DNA vaccines. The
value of a number of novel BCG replacement strategies will also
become clearer. Systematic study of heterologous platform combi-
nations using common antigen sets is now underway for many of
these approaches.
A variety of highly novel vaccine candidates are being devel-
oped by academia, industry, and expert consortia, utilizing a
number of innovative and diverse approaches. There is renewed
emphasis on prevention of infection through antibody-mediated
or other immunologic mechanisms; in addition, optimal glycolipid
constructs and adjuvants that induce responses via the CD1 sys-
tem, as well as antigens for induction of gamma delta T cells or
mucosal invariant T cells (MAITS), are being explored. All of these
approaches are high risk/high reward investigations that expand
the immunologic response space being probed by TB vaccine can-
didates. Testing of these novel candidates is being facilitated by the
concurrent development of new animal models of natural trans-
mission. The models include human- or primate-to-guinea pig
transmission, as well as novel macaque-to-macaque transmission
in an environmentally controlled setting. While these programs
progress, signiﬁcant attempts will be undertaken to build a safe
mycobacterial construct that can be used in a human TB challenge
model, which would open wide the ﬁeld of early clinical vaccine
assessment. The strain of Mtb used will need to exhibit some degree
of low level replication, a failsafe kill switch and a second attenua-
tion mechanism to help ensure safety. The strain must be modiﬁed
such that the bacterial burden can be easily measured in the chal-
lenged subject through the imaging of a luminescent marker or by
measuring a soluble, secreted marker in blood, exhaled air or urine.
There is also an important need to use a more rational approach
for selection of TB vaccine candidates for future studies [15]. First,
there is a need to ensure that each vaccine carried forward into
efﬁcacy studies addresses a new hypothesis, rather than pursuing
a vaccine approach that has already been moved forward into efﬁ-
cacy trials. It will be critical to then choose only the best vaccine
candidate among those that are likely to induce a similar magni-
tude and phenotype of immune responses. From candidates that
have similar target proﬁles, head to head comparisons of candidates
in animal and early human studies would be optimal, and mech-
anisms and incentives (such as support from funding agencies) to
do such comparisons are needed. This approach also implies the
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eed for a diverse and robust pipeline of candidates representing
ot just a set of minor improvements but truly novel approaches
hat test different immunologic hypotheses.
. Likelihood for ﬁnancing
TB continues to be a massive problem in both infants and young
dults. Accordingly, it is highly likely that GAVI would support a
B vaccine that could save hundreds of thousands of lives. TB is
he 9th leading cause of death in the world, and it is inconceiv-
ble that an effective intervention for the poorest countries would
ot be supported by the global health community. The TB research
nd funder community is attempting to organize a global portfolio
anagement and information secretariat, known by the acronym
TBVP (Global TB Vaccine Partnership), which may  take shape in
he coming year. This group aims to have the following functions:
. Attract additional funders for TB vaccine R&D.
. Put TB vaccine R&D higher on the global health and research
agenda AND on global political agenda.
. Develop a consensus on TB vaccine priorities to guide funding
allocation decisions (a. portfolio management recommendations
on clinical trials and its funding allocation; b. overall scientiﬁc
strategy TB vaccine development).
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